Proteomic Profiling of HDL in Newly Diagnosed Breast Cancer Based on Tumor Molecular Classification and Clinical Stage of Disease
Abstract
:1. Introduction
2. Materials and Methods
2.1. Population of the Study
2.2. Blood Collection and Determination of Plasma Lipid Profile
2.3. HDL Isolation
2.4. HDL Digestion for Proteomics
2.5. Liquid Chromatography–Mass Spectrometry (LC-MS/MS) Analyses
2.6. Sample Randomization and Quality Controls (QCs)
2.7. MS Data Processing
2.8. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Barzaman, K.; Karami, J.; Zarei, Z.; Hosseinzadeh, A.; Kazemi, M.H.; Moradi-Kalbolandi, S.; Safari, E.; Farahmand, L. Breast cancer: Biology, biomarkers, and treatments. Int. Immunopharmacol. 2020, 84, 106535. [Google Scholar] [CrossRef] [PubMed]
- Lofterød, T.; Mortensen, E.S.; Nalwoga, H.; Wilsgaard, T.; Frydenberg, H.; Risberg, T.; Eggen, A.E.; McTiernan, A.; Aziz, S.; Wist, E.A.; et al. Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes. BMC Cancer 2018, 18, 654. [Google Scholar] [CrossRef]
- Sawada, M.I.B.A.C.; de Fátima Mello Santana, M.; Reis, M.; de Assis, S.I.S.; Pereira, L.A.; Santos, D.R.; Nunes, V.S.; Correa-Giannella, M.L.C.; Gebrim, L.H.; Passarelli, M. Increased plasma lipids in triple-negative breast cancer and impairment in HDL functionality in advanced stages of tumors. Sci. Rep. 2023, 13, 8998. [Google Scholar] [CrossRef] [PubMed]
- Samadi, S.; Ghayour-Mobarhan, M.; Mohammadpour, A.; Farjami, Z.; Tabadkani, M.; Hosseinnia, M.; Miri, M.; Heydari-Majd, M.; Mehramiz, M.; Rezayi, M.; et al. High-density lipoprotein functionality and breast cancer: A potential therapeutic target. J. Cell. Biochem. 2019, 120, 5756–5765. [Google Scholar] [CrossRef] [PubMed]
- Kucharska-Newton, A.M.; Rosamond, W.D.; Mink, P.J.; Alberg, A.J.; Shahar, E.; Folsom, A.R. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann. Epidemiol. 2008, 18, 671–677. [Google Scholar] [CrossRef] [PubMed]
- Fan, Y.; Ding, X.; Wang, J.; Ma, F.; Yuan, P.; Li, Q.; Zhang, P.; Xu, B. Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs. Int. J. Biol. Markers 2015, 30, 200–207. [Google Scholar] [CrossRef] [PubMed]
- Beeghly-Fadiel, A.; Khankari, N.K.; Delahanty, R.J.; Shu, X.O.; Lu, Y.; Schmidt, M.K.; Bolla, M.K.; Michailidou, K.; Wang, Q.; Dennis, J.; et al. A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. Int. J. Epidemiol. 2020, 49, 1117–1131. [Google Scholar] [CrossRef] [PubMed]
- Lin, C.C.; Gray, P.J.; Jemal, A.; Efstathiou, J.A. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J. Natl. Cancer Inst. 2015, 107, djv119. [Google Scholar] [CrossRef]
- His, M.; Dartois, L.; Fagherazzi, G.; Boutten, A.; Dupré, T.; Mesrine, S.; Boutron-Ruault, M.C.; Clavel-Chapelon, F.; Dossus, L. Associations between serum lipids and breast cancer incidence and survival in the E3N prospective cohort study. Cancer Causes Control 2017, 28, 77–88. [Google Scholar] [CrossRef]
- Graham, A. Modulation of the Cellular microRNA Landscape: Contribution to the Protective Effects of High-Density Lipoproteins (HDL). Biology 2023, 12, 1232. [Google Scholar] [CrossRef]
- Davidson, W.S.; Shah, A.S.; Sexmith, H.; Gordon, S.M. The HDL Proteome Watch: Compilation of studies leads to new insights on HDL function. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2022, 1867, 159072. [Google Scholar] [CrossRef] [PubMed]
- The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 2012, 490, 61–70. [Google Scholar] [CrossRef] [PubMed]
- Mertins, P.; Mani, D.R.; Ruggles, K.V.; Gillette, M.A.; Clauser, K.R.; Wang, P.; Wang, X.; Qiao, J.W.; Cao, S.; Petralia, F.; et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 2016, 534, 55–62. [Google Scholar] [CrossRef] [PubMed]
- Krug, K.; Jaehnig, E.J.; Satpathy, S.; Blumenberg, L.; Karpova, A.; Anurag, M.; Miles, G.; Mertins, P.; Geffen, Y.; Tang, L.C.; et al. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell 2020, 183, 1436–1456.e31. [Google Scholar] [CrossRef] [PubMed]
- Goldhirsch, A.; Wood, W.C.; Coates, A.S.; Gelber, R.D.; Thürlimann, B.; Senn, H.J.; Panel Members. Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann. Oncol. 2011, 22, 1736–1747. [Google Scholar] [CrossRef] [PubMed]
- Gospodarowicz, M.K.; Wittekind, C.; Brierley, J.D. (Eds.) TNM Classification of Malignant Tumours, 8th ed.; Wiley-Blackwell: Hoboken, NJ, USA, 2016; 272p, ISBN 978-1-119-26357-9. [Google Scholar]
- Ronsein, G.E.; Pamir, N.; von Haller, P.D.; Kim, D.S.; Oda, M.N.; Jarvik, G.P.; Vaisar, T.; Heinecke, J.W. Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics. J. Proteom. 2015, 113, 388–399. [Google Scholar] [CrossRef] [PubMed]
- Silva, A.R.M.; Toyoshima, M.T.K.; Passarelli, M.; Di Mascio, P.; Ronsein, G.E. Comparing Data-Independent Acquisition and Parallel Reaction Monitoring in Their Abilities To Differentiate High-Density Lipoprotein Subclasses. J. Proteome Res. 2020, 19, 248–259. [Google Scholar] [CrossRef] [PubMed]
- Rappsilber, J.; Mann, M.; Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2007, 2, 1896–1906. [Google Scholar] [CrossRef] [PubMed]
- Souza Junior, D.R.; Silva, A.R.M.; Ronsein, G.E. Strategies for consistent and automated quantification of HDL proteome using data-independent acquisition. J. Lipid Res. 2023, 64, 100397. [Google Scholar] [CrossRef] [PubMed]
- Souza Junior, D.R.; Silva, A.R.M.; Rosa-Fernandes, L.; Reis, L.R.; Alexandria, G.; Bhosale, S.D.; Ghilardi, F.R.; Dalçóquio, T.F.; Bertolin, A.J.; Nicolau, J.C.; et al. HDL proteome remodeling associates with COVID-19 severity. J. Clin. Lipidol. 2021, 15, 796–804. [Google Scholar] [CrossRef]
- Okuturlar, Y.; Gunaldi, M.; Kocoglu, H.; Hursitoglu, M.; Gedikbasi, A.; Acarer, D.; Harmankaya, O.; Kumbasar, A. Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer. J. Cancer Res. Ther. 2018, 14, S362–S367. [Google Scholar] [CrossRef] [PubMed]
- Arenas, M.; García-Heredia, A.; Cabré, N.; Luciano-Mateo, F.; Hernández-Aguilera, A.; Sabater, S.; Bonet, M.; Gascón, M.; Fernández-Arroyo, S.; Fort-Gallifa, I.; et al. Effect of radiotherapy on activity and concentration of serum paraoxonase-1 in breast cancer patients. PLoS ONE 2017, 12, e0188633. [Google Scholar] [CrossRef] [PubMed]
- Prakash, M.D.; Fraser, S.; Boer, J.C.; Plebanski, M.; de Courten, B.; Apostolopoulos, V. Anti-Cancer Effects of Carnosine—A Dipeptide Molecule. Molecules 2021, 26, 1644. [Google Scholar] [CrossRef] [PubMed]
- Vowinkel, T.; Mori, M.; Krieglstein, C.F.; Russell, J.; Saijo, F.; Bharwani, S.; Turnage, R.H.; Davidson, W.S.; Tso, P.; Granger, D.N.; et al. Apolipoprotein A-IV inhibits experimental colitis. J. Clin. Investig. 2004, 114, 260–269. [Google Scholar] [CrossRef] [PubMed]
- Goldberg, I.J.; Scheraldi, C.A.; Yacoub, L.K.; Sexana, U.; Bisgaier, C.L. Lipoprotein apoC-II activation of lipoprotein lipase. Molulation by apolipoprotein A-IV. J. Biol. Chem. 1990, 265, 4266–4272. [Google Scholar] [CrossRef] [PubMed]
- Steinmetz, A.; Barbaras, A.; Ghalim, N.; Clavey, V.; Fruchart, J.C.; Aihaud, G. Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterpç efflux from adipose cells. J. Biol. Chem. 1990, 265, 7859–7863. [Google Scholar] [CrossRef] [PubMed]
- Custodio, A.; López-Farré, A.J.; Zamorano-León, J.J.; Mateos-Cáceres, P.J.; Macaya, C.; Caldés, T.; de la Hoya, M.; Olivera, E.; Puente, J.; Díaz-Rubio, E.; et al. Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers. J. Cancer Res. Clin. Oncol. 2012, 138, 867–875. [Google Scholar] [CrossRef] [PubMed]
- Nasim, F.U.; Ejaz, S.; Ashraf, M.; Asif, A.R.; Oellerich, M.; Ahmad, G.; Malik, G.A.; Attiq-Ur-Rehman. Potential biomarkers in the sera of breast cancer patients from bahawalpur, pakistan. Biomark. Cancer 2012, 4, 19–34. [Google Scholar] [CrossRef] [PubMed]
- Escher, N.; Kaatz, M.; Melle, C.; Hipler, C.; Ziemer, M.; Driesch, D.; Wollina, U.; von Eggeling, F. Posttranslational modifications of transthyretin are serum markers in patients with mycosis fungoides. Neoplasia 2007, 9, 254–259. [Google Scholar] [CrossRef]
- Zhang, Y.; Shi, J.; Luo, J.; Liu, C.; Zhu, L. Metabolic heterogeneity in early-stage lung adenocarcinoma revealed by RNA-seq and scRNA-seq. Clin. Transl. Oncol. 2023, 25, 1844–1855. [Google Scholar] [CrossRef]
- Li, P.; Lin, Z.; Liu, Q.; Chen, S.; Gao, X.; Guo, W.; Gong, F.; Wei, J.; Lin, H. Enhancer RNA SLIT2 Inhibits Bone Metastasis of Breast Cancer Through Regulating P38 MAPK/c-Fos Signaling Pathway. Front. Oncol. 2021, 11, 743840. [Google Scholar] [CrossRef] [PubMed]
- Høgdall, C.K.; Christensen, L.; Clemmensen, I. Tetranektin, et plasma- og vaevsprotein--en prognostisk markør for mamma- og ovariekarcinom [Tetranectin, a plasma and tissue protein--a prognostic marker of breast and ovarian cancer]. Ugeskr. Laeger 1994, 156, 6190–6195. [Google Scholar] [PubMed]
- Lundstrøm, M.S.; Høgdall, C.K.; Nielsen, A.L.; Nyholm, H.C. Serum tetranectin and CA125 in endometrial adenocarcinoma. Anticancer Res. 2000, 20, 3903–3906. [Google Scholar]
- Deng, X.; Høgdall, E.V.; Høgdall, C.K.; Nørgaard-Pedersen, B.; Jørgensen, M.; Nielsen, H.; Engelholm, S.A. The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer. Gynecol. Oncol. 2000, 79, 416–419. [Google Scholar] [CrossRef] [PubMed]
- Høgdall, C.K.; Mogensen, O.; Tabor, A.; Mogensen, B.; Jakobsen, A.K.; Nørgaard-Pedersen, B.; Larsen, S.O.; Clemmensen, I. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors. Gynecol. Oncol. 1995, 56, 22–28. [Google Scholar] [CrossRef] [PubMed]
- Høgdall, C.K.; Sölétormos, G.; Nielsen, D.; Nørgaard-Pedersen, B.; Dombernowsky, P.; Clemmensen, I. Prognostic value of serum tetranectin in patients with metastatic breast cancer. Acta Oncol. 1993, 32, 631–636. [Google Scholar] [CrossRef] [PubMed]
- Ignacio, R.M.C.; Gibbs, C.R.; Kim, S.; Lee, E.S.; Adunyah, S.E.; Son, D.S. Serum amyloid A predisposes inflammatory tumor microenvironment in triple negative breast cancer. Oncotarget 2019, 10, 511–526. [Google Scholar] [CrossRef]
- Zhang, G.; Liu, J.; Wu, L.; Fan, Y.; Sun, L.; Qian, F.; Chen, D.; Ye, R.D. Elevated Expression of Serum Amyloid A 3 Protects Colon Epithelium Against Acute Injury Through TLR2-Dependent Induction of Neutrophil IL-22 Expression in a Mouse Model of Colitis. Front. Immunol. 2018, 9, 1503. [Google Scholar] [CrossRef]
- Gordon, S.M.; Hofmann, S.; Askew, D.S.; Davidson, W.S. High density lipoprotein: It’s not just about lipid transport anymore. Trends Endocrinol. Metab. 2011, 22, 9–15. [Google Scholar] [CrossRef]
- Levine, A.J.; Puzio-Kuter, A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330, 1340–1344. [Google Scholar] [CrossRef]
- Zamanian-Daryoush, M.; DiDonato, J.A. Apolipoprotein A-I and Cancer. Front. Pharmacol. 2015, 6, 265. [Google Scholar] [CrossRef] [PubMed]
- Gonçalves, A.; Esterni, B.; Bertucci, F.; Sauvan, R.; Chabannon, C.; Cubizolles, M.; Bardou, V.J.; Houvenaegel, G.; Jacquemier, J.; Granjeaud, S.; et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 2006, 25, 981–989. [Google Scholar] [CrossRef]
- Liu, J.X.; Yuan, Q.; Min, Y.L.; He, Y.; Xu, Q.H.; Li, B.; Shi, W.Q.; Lin, Q.; Li, Q.H.; Zhu, P.W.; et al. Apolipoprotein A1 and B as risk factors for development of intraocular metastasis in patients with breast cancer. Cancer Manag. Res. 2019, 11, 2881–2888. [Google Scholar] [CrossRef] [PubMed]
- Torres-Romero, J.C.; Lara-Riegos, J.C.; Parra, E.A.E.; Sánchez, V.F.; Arana-Argáez, V.E.; Uc-Colli, S. Lipoproteomics: Methodologies and Analysis of Lipoprotein-Associated Proteins along with the Drug Intervention. In Drug Design-Novel Advances in the Omics Field and Applications; IntechOpen: London, UK, 2021. [Google Scholar] [CrossRef]
- Bobin-Dubigeon, C.; Nazih, H.; Blanchard, V.; Croyal, M.; Bard, J.M. Circulating HDL and Non-HDL Associated Apolipoproteins and Breast Cancer Severity. J. Clin. Med. 2022, 11, 1345. [Google Scholar] [CrossRef]
- Zhang, Y.; Fang, X.; Sun, Y. IGHG1 promotes malignant progression in breast cancer cells through the regulation of AKT and VEGF signaling. Biomol. Biomed. 2023, 23, 616–623. [Google Scholar] [CrossRef]
- Sankaranarayanan, S.; Oram, J.F.; Asztalos, B.F.; Vaughan, A.M.; Lund-Katz, S.; Adorni, M.P.; Phillips, M.C.; Rothblat, G.H. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J. Lipid Res. 2009, 50, 275–284. [Google Scholar] [CrossRef] [PubMed]
- Avena, P.; Casaburi, I.; Zavaglia, L.; Nocito, M.C.; La Padula, D.; Rago, V.; Dong, J.; Thomas, P.; Mineo, C.; Sirianni, R.; et al. 27-Hydroxycholesterol Binds GPER and Induces Progression of Estrogen Receptor-Negative Breast Cancer. Cancers 2022, 14, 1521. [Google Scholar] [CrossRef] [PubMed]
- Campos, A.L.; Sawada, M.I.B.A.C.; Santana, M.F.M.; Iborra, R.T.; de Assis, S.I.S.; Reis, M.; de Carvalho, J.X.; Gebrim, L.H.; Passarelli, M. The increased antioxidant action of HDL is independent of HDL cholesterol plasma levels in triple-negative breast cancer. Front. Oncol. 2023, 13, 1111094. [Google Scholar] [CrossRef] [PubMed]
- Santana, M.F.M.; Sawada, M.I.B.A.C.; Santos, A.S.; Reis, M.; Xavier, J.; Côrrea-Giannella, M.L.; Hirata, A.H.L.; Gebrim, L.H.; Soriano, F.G.; Camacho, C.P.; et al. Increased Expression of miR-223-3p and miR-375-3p and Anti-Inflammatory Activity in HDL of Newly Diagnosed Women in Advanced Stages of Breast Cancer. Int. J. Mol. Sci. 2023, 24, 12762. [Google Scholar] [CrossRef]
- Liang, X.; Zhao, J.; Hajivandi, M.; Wu, R.; Tao, J.; Amshey, J.W.; Pope, R.M. Quantification of membrane and membrane-bound proteins in normal and malignant breast cancer cells isolated from the same patient with primary breast carcinoma. J. Proteome Res. 2006, 5, 2632–2641. [Google Scholar] [CrossRef]
- Suman, S.; Basak, T.; Gupta, P.; Mishra, S.; Kumar, V.; Sengupta, S.; Shukla, Y. Quantitative proteomics revealed novel proteins associated with molecular subtypes of breast cancer. J. Proteom. 2016, 148, 183–193. [Google Scholar] [CrossRef] [PubMed]
- Yang, M.; Liu, F.; Higuchi, K.; Sawashita, J.; Fu, X.; Zhang, L.; Zhang, L.; Fu, L.; Tong, Z.; Higuchi, K. Serum amyloid A expression in the breast cancer tissue is associated with poor prognosis. Oncotarget 2016, 7, 35843–35852. [Google Scholar] [CrossRef] [PubMed]
- Hansen, M.T.; Forst, B.; Cremers, N.; Quagliata, L.; Ambartsumian, N.; Grum-Schwensen, B.; Klingelhöfer, J.; Abdul-Al, A.; Herrmann, P.; Osterland, M.; et al. A link between inflammation and metastasis: Serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4. Oncogene 2015, 34, 424–435. [Google Scholar] [CrossRef] [PubMed]
- Sack, G.H. Serum amyloid A (SAA) proteins. Subcell. Biochem. 2020, 94, 421–436. [Google Scholar] [PubMed]
- Rybinska, I.; Mangano, N.; Romero-Cordoba, S.L.; Regondi, V.; Ciravolo, V.; De Cecco, L.; Maffioli, E.; Paolini, B.; Bianchi, F.; Sfondrini, L.; et al. SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness. Int. J. Cancer 2024, 154, 1842–1856. [Google Scholar] [CrossRef] [PubMed]
- Kuhajda, F.P.; Piantadosi, S.; Pasternack, G.R. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N. Engl. J. Med. 1989, 321, 636–641. [Google Scholar] [CrossRef] [PubMed]
- Asleh, K.; Negri, G.L.; Spencer Miko, S.E.; Colborne, S.; Hughes, C.S.; Wang, X.Q.; Gao, D.; Gilks, C.B.; Chia, S.K.L.; Nielsen, T.O.; et al. Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. Nat. Commun. 2022, 13, 896. [Google Scholar] [CrossRef] [PubMed]
- Jeanmard, N.; Bissanum, R.; Sriplung, H.; Charoenlappanit, S.; Roytrakul, S.; Navakanitworakul, R. Proteomic profiling of urinary extracellular vesicles differentiates breast cancer patients from healthy women. PLoS ONE 2023, 18, e0291574. [Google Scholar] [CrossRef] [PubMed]
- Xu, G.; Huang, R.; Wumaier, R.; Lyu, J.; Huang, M.; Zhang, Y.; Chen, Q.; Liu, W.; Tao, M.; Li, J.; et al. Proteomic Profiling of Serum Extracellular Vesicles Identifies Diagnostic Signatures and Therapeutic Targets in Breast Cancer. Cancer Res. 2024. [Google Scholar] [CrossRef]
- Jensen, M.K.; Aroner, S.A.; Mukamal, K.J.; Furtado, J.D.; Post, W.S.; Tsai, M.Y.; Tjønneland, A.; Polak, J.F.; Rimm, E.B.; Overvad, K.; et al. High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts. Circulation 2018, 137, 1364–1373. [Google Scholar] [CrossRef]
- Cheung, M.C.; Vaisar, T.; Han, X.; Heinecke, J.W.; Albers, J.J. Phospholipid transfer protein in human plasma associates with proteins linked to immunity and inflammation. Biochemistry 2010, 49, 7314–7322. [Google Scholar] [CrossRef] [PubMed]
CT | BC | p | |||
---|---|---|---|---|---|
n | 143 | 141 | |||
Age (year) | 50 (38–59) | 56 (49–63) | <0.0001 | ||
BMI (kg/m2) | 27 (24–31) | 27 (24–31) | 0.6391 | ||
n | % | n | % | ||
Pre-menopause | 72 | 50 | 49 | 34 | |
Post-menopause | 69 | 48 | 92 | 65 |
LA | LB | HER2 | TNBC | p | |||||
---|---|---|---|---|---|---|---|---|---|
n | 43 | 54 | 24 | 20 | ns | ||||
Age (year) | 61 (52–65) | 53 (46–61) | 57 (52–61) | 56 (41–61) | ns | ||||
BMI (kg/m2) | 27 (24–30) | 27 (24–30) | 27 (24–31) | 28 (23–32) | ns | ||||
n | % | n | % | n | % | n | % | ||
Pre-menopause | 10 | 23 | 26 | 48 | 5 | 20 | 8 | 40 | |
Post-menopause | 33 | 46 | 28 | 51 | 19 | 79 | 12 | 60 |
CT | BC | p | |
---|---|---|---|
n | 143 | 141 | |
TC (mg/dL) | 173 (153–202) | 186 (158–212) | 0.4272 |
TG (mg/dL) | 84 (59–119) | 92 (68–115) | 0.5551 |
apoB (mg/dL) | 110 (89–137) | 110 (81–141) | 0.5615 |
HDLc (mg/dL) | 42 (35–51) | 41 (34–49) | 0.6909 |
LDLc (mg/dL) | 112 (94–134) | 117 (98–144) | 0.6348 |
Non-HDLc (mg/dL) | 129 (129–158) | 135 (116–165) | 0.5720 |
TC/apoB | 1.5 (1.3–1.9) | 1.7 (1.3–2.0) | 0.1595 |
TG/HDLc | 1.8 (1.3–3.0) | 2.2 (1.4–3.2) | 0.5864 |
LA | LB | HER2 | TNBC | p | |
---|---|---|---|---|---|
n | 43 | 54 | 24 | 20 | |
TC (mg/dL) | 195 (162–232) | 175 (156–209) | 173 (153–197) | 191 (164–210) | ns |
TG (mg/dL) | 104 (66–139) | 84 (68–112) | 85 (67–100) | 99 (82–115) | ns |
apoB (mg/dL) | 129 (91–148) | 98 (79–126) | 103 (80–137) | 134 (95–173) | ns |
HDLc (mg/dL) | 41 (34–48) | 42 (32–53) | 45 (35–51) | 40 (34–44) | ns |
LDLc (mg/dL) | 122 (103–159) | 111 (96–140) | 116 (84–137) | 128 (97–149) | ns |
Non-HDLc (mg/dL) | 150 (122–190) | 130 (108–162) | 133 (103–153) | 148 (129–175) | ns |
TC/apoB | 1.7 (1.3–2.0) | 1.8 (1.5–2.4) | 1.8 (1.3–1.9) | 1.4 (1.1–1.9) | ns |
TG/HDLc | 2.2 (1.5–3.1) | 2.0 (1.3–3.2) | 1.6 (1.2–3.1) | 2.4 (1.8–3.3) | ns |
Abbreviations | Proteins |
---|---|
Lipid metabolism | |
ApoA-4 | Apolipoproteins A-4 |
ApoA-1 | Apolipoprotein A-1 |
Apo-C-2 | Apolipoprotein C-2 |
ApoC-4 | Apolipoprotein C-4 |
LPA | Apolipoprotein (a) |
LCAT | Lecithin cholesterol acyltransferase |
Inflammatory acute phase protein | |
SAA1 | Serum Amyloid A type 1 |
SAA2 | Serum Amyloid A type 2 |
HPR | Haptoglobin-related protein |
Complement system | |
C3 | Complement C3 |
C9 | Complement C9 |
CFB | Complement Factor B |
C4B | Complement 4b |
Antioxidants | |
PON1 | Paraoxonase-1 |
CNDP1 | Carnosine dipeptidase 1 |
Transport proteins | |
GC | Vitamin D-binding protein or group-specific component |
TTR | Transthyretin |
IGHM | Immunoglobulin Mu heavy chain constant region |
IGLC2/3 | Immunoglobulin lambda constant 2/3 |
IGHG1 | Immunoglobulin heavy constant gamma 1 |
Tissue remodeling | |
CLEC3B | Tetranectin |
Serine protease inhibitors | |
SERPIN 3 | Serpin 3 |
PLG | Plasminogen |
LRG1 | Leucine-rich alpha-2 glycoprotein 1 |
A2M | Alpha2-macroglobulin |
Lower Expression in TNBC | ||||
---|---|---|---|---|
Protein | vs. LA | vs. LB | vs. HER2 | |
ApoA-1 | AUC p | 0.7017 0.0104 | 0.6936 0.0107 | 0.7104 0.0173 |
ApoC-2 | AUC p | 0.7366 0.0027 | 0.6891 0.0127 | ns |
ApoA-2 | AUC p | 0.7279 0.0038 | 0.7091 0.0059 | 0.7438 0.0058 |
ApoC-4 | AUC p | 0.7134 0.0067 | ns | 0.6958 0.0267 |
Higher expression in TNBC | ||||
Protein | vs. LA | vs. LB | vs. HER2 | |
C3 | AUC p | 0.6965 0.0126 | 0.7259 0.0029 | 0.7365 0.0075 |
IGLC2/3 | AUC p | 0.7140 0.0066 | 0.6450 0.0560 | 0.7375 0.0072 |
Serpin | AUC p | 0.7240 0.0052 | 0.6885 0.0148 | 0.7588 0.0039 |
IGHG1 | AUC p | 0.6988 0.0116 | 0.6676 0.0276 | 0.7333 0.0083 |
C9 | AUC p | 0.7058 0.0090 | 0.6973 0.0093 | 0.7458 0.0054 |
LRG1 | AUC p | 0.7360 0.0027 | 0.6505 0.0474 | 0.7573 0.0036 |
C4B | AUC p | 0.7302 0.0035 | 0.7091 0.0059 | 0.7042 0.0209 |
CFB | AUC p | 0.6779 0.0239 | ns | 0.7313 0.0089 |
GC | AUC p | 0.7110 0.0074 | ns | 0.7281 0.0099 |
PLG | AUC p | 0.7295 0.0042 | ns | ns |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Santana, M.d.F.M.; Sawada, M.I.B.A.C.; Junior, D.R.S.; Giacaglia, M.B.; Reis, M.; Xavier, J.; Côrrea-Giannella, M.L.; Soriano, F.G.; Gebrim, L.H.; Ronsein, G.E.; et al. Proteomic Profiling of HDL in Newly Diagnosed Breast Cancer Based on Tumor Molecular Classification and Clinical Stage of Disease. Cells 2024, 13, 1327. https://doi.org/10.3390/cells13161327
Santana MdFM, Sawada MIBAC, Junior DRS, Giacaglia MB, Reis M, Xavier J, Côrrea-Giannella ML, Soriano FG, Gebrim LH, Ronsein GE, et al. Proteomic Profiling of HDL in Newly Diagnosed Breast Cancer Based on Tumor Molecular Classification and Clinical Stage of Disease. Cells. 2024; 13(16):1327. https://doi.org/10.3390/cells13161327
Chicago/Turabian StyleSantana, Monique de Fatima Mello, Maria Isabela Bloise Alves Caldas Sawada, Douglas Ricardo Souza Junior, Marcia Benacchio Giacaglia, Mozania Reis, Jacira Xavier, Maria Lucia Côrrea-Giannella, Francisco Garcia Soriano, Luiz Henrique Gebrim, Graziella Eliza Ronsein, and et al. 2024. "Proteomic Profiling of HDL in Newly Diagnosed Breast Cancer Based on Tumor Molecular Classification and Clinical Stage of Disease" Cells 13, no. 16: 1327. https://doi.org/10.3390/cells13161327